The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | CTCs as a prognostic factor in multiple myeloma
Ioannis Kostopoulos, MSc, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses the results of a study which indicated that increased levels of circulating tumor cells (CTCs) are a strong prognostic indicator for both transplant-eligible and transplant-ineligible patients with multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
